Oxurion NV (OXUR) - Financial and Strategic SWOT Analysis Review

October 2021 | 53 pages | ID: OD9C53A710D6EN
GlobalData

Abstracts

Oxurion NV (OXUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oxurion NV (Oxurion), formerly ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer therapeutics. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). Oxurion’s product pipeline includes THR-687, a pan-RGD integrin antagonist being developed for the treatment of diabetic retinopathy, and THR-149, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema (DME). It has commercialization agreements with companies such as BioInvent International, Quintiles Outcome Sciences, Bicycle Therapeutics, Galapagos, Parexel, INC Research, Grifols Inc, Patheon, and Alcon. It has a presence in Belgium, Ireland, and the US. Oxurion is headquartered in Leuven, Flemish Brabant, Belgium.

Oxurion NV Key Recent Developments

Aug 05,2021: OXURION to Participate in Upcoming Investor Meetings
May 17,2021: OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer
Apr 30,2021: OXURION presenting scientific data at ARVO 2021 Annual Meeting
Mar 31,2021: OXURION to Participate in Upcoming Investor Meetings
Feb 23,2021: H.C. Wainwright Global Life Sciences Conference (Virtual)

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Oxurion NV - Key Facts
Oxurion NV - Key Employees
Oxurion NV - Key Employee Biographies
Oxurion NV - Major Products and Services
Oxurion NV - History
Oxurion NV - Company Statement
Oxurion NV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Oxurion NV - Business Description
Other Break-up: Income from Royalties
Performance
Other Break-up: Sales
Performance
Oxurion NV - Corporate Strategy
Oxurion NV - SWOT Analysis
SWOT Analysis - Overview
Oxurion NV - Strengths
Oxurion NV - Weaknesses
Oxurion NV - Opportunities
Oxurion NV - Threats
Oxurion NV - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oxurion NV, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 05, 2021: OXURION to Participate in Upcoming Investor Meetings
May 17, 2021: OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer
Apr 30, 2021: OXURION presenting scientific data at ARVO 2021 Annual Meeting
Mar 31, 2021: OXURION to Participate in Upcoming Investor Meetings
Feb 23, 2021: H.C. Wainwright Global Life Sciences Conference (Virtual)
Jan 20, 2021: Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
Oct 15, 2020: Oxurion business update – Q3 2020
Oct 13, 2020: Oxurion appoints Tom Graney, CFA as chief financial officer
Oct 05, 2020: Oxurion to host Virtual R&D Investor Day on 15 October 2020
Sep 20, 2020: Oxurion: Interim Financial Report Half-year results as at June 30, 2020

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Oxurion NV, Key Facts
Oxurion NV, Key Employees
Oxurion NV, Key Employee Biographies
Oxurion NV, Major Products and Services
Oxurion NV, History
Oxurion NV, Other Locations
Oxurion NV, Subsidiaries
Oxurion NV, Key Competitors
Oxurion NV, Ratios based on current share price
Oxurion NV, Annual Ratios
Oxurion NV, Annual Ratios (Cont...1)
Oxurion NV, Annual Ratios (Cont...2)
Oxurion NV, Interim Ratios
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oxurion NV, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Oxurion NV, Performance Chart (2016 - 2020)
Oxurion NV, Ratio Charts
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oxurion NV, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021